Medicom Group, a Canadian surgical and respiratory mask manufacturer, has created a new manufacturing subsidiary, Meltech Innovation Canada, to produce the inner filter material used in the surgical, paediatric and N95-type respiratory masks.
As a result of this and other local initiatives, Canada will no longer be the only OECD-country that does not have domestic production of this critical melt blown polypropylene filter.
Located in the greater Montreal area, the new manufacturing facility will create 21 new jobs and 16 new co-op positions for university students. The Canadian government has committed to investing up to $28.99 million through the Strategic Innovation Fund.
“Our top priority is protecting the safety and security of Canadians. We are investing to ensure we can produce critical PPE here in Canada,” minister of Innovation, Science and Industry François-Philippe Champagne said.
“Today’s investment in Meltech is an important step toward improving Canada’s resilience and pandemic preparedness. This investment will ensure that Canadian frontline healthcare workers continue to have a reliable supply of the critical PPE they need, while creating good jobs here in Montreal.”
This will greatly improve Canada’s medical autonomy, according to Medicom founder and CEO Ronald Reuben.
“Establishing this new plant will help to ensure that Canada never again experiences the PPE shortages we did in March 2020, when the global supply chain was under extreme strain,” Reuben said.
“Thanks to this partnership with the government of Canada, Meltech will initially produce the filter material needed to manufacture the equivalent of tens of millions masks right here in Canada, with more capacity planned.”
From the first shovel of earth to production, the Meltech facility will be designed to mitigate impact on the environment. Connected to this facility, Medicom will establish a new research and development centre to drive innovation in PPE.
“The new PPE R&D centre, based in Quebec, will be unique in Canada,” Medicom COO Guillaume Laverdure said.
“Combining our own expertise developed over the past thirty years in Canada, the US, Europe and Asia with various industrial and academic partners, we are aiming to become a world leader in medical innovation. We are even more pleased to be doing this from our home base in Quebec.”